参考文献/References:
[1] Andrade J ,Khairy P,Dobrev D,et al. The clinical profile and pathophysiology of atrial fibrillation:relationships among clinical features,epidemiology,and mechanisms[J]. Circ Res,2014,114(9):1453-1468.
[2] Freeman JV,Wang Y,Akar J,et al. National trends in atrial fibrillation hospitalization,readmission,and mortality for medicare beneficiaries,1999-2013[J]. Circulation,2014,135(13):1227-1239.
[3] Heijman J,Voigt N,Nattel S,et al. Cellular and molecular electrophysiology of atrial fibrillation initiation ,maintenance,and progression[J]. Circ Res,2014,114(9):1483-1499.
[4] Amin J, Boche D, Rakic S. What do we know about the inflammasome in humans? [J]. Brain Pathol,2017,27(2):192-204.
[5] Schroder K,Tschopp J. The inflammasome[J]. Cell,2010,140(6):821-832.
[6] Kim JK,Shin DM,Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation[J]. Cell Mol Immunol,2016,13(2):148-159.
[7] He Y,Hara H,Nú?ez G. Mechanism and regulation of NLRP3 inflammasome activation[J]. Trends Biochem Sci,2016,41(12):1012-1021.
[8] Xue Y,Enosi Tuipulotu D,Tan WH,et al. Emerging activators and regulators of inflammasomes and pyroptosis[J]. Trends Immunol,2019,40(11),1035-1052.
[9] Sutterwala FS,Haasken S,Cassel SL. Mechanism of NLRP3 inflammasome activation[J]. Ann N Y Acad Sci,2014,1319(1):82-95.
[10] Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction[J]. Int Heart J,2014,55(2):101-105.
[11] Sun Y,Abbondante S,Karmakar M,et al. Neutrophil caspase-11 is required for cleavage of caspase-1 and secretion of IL-1β in aspergillus fumigatus infection[J]. J Immunol,?2018,201(9):2767-2775.
[12] Eldridge MJG,Sanchez-Garrido J,Hoben GF,et al. The atypical ubiquitin E2 conjugase UBE2L3 is an indirect caspase-1 target and controls IL-1β secretion by inflammasomes[J]. Cell Rep,2017,18(5):1285-1297.
[13] Sallman DA,Cluzeau T,Basiorka AA. Unraveling the pathogenesis of MDS:The NLRP3 inflammasome and pyroptosis drive the MDS Phenotype[J]. Front Oncol,?2016,6:151.
[14] Liberale L,Carbone F,Camici GG,et al. IL-1β and statin treatment in patients with myocardial infarction and diabetic cardiomyopathy[J]. J Clin Med,?2019,8(11). 1764.
[15] Thawkar BS,Kaur G. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia:novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease[J]. J Neuroimmunol,2019,326:62-74.
[16] Yang Y,Wang H,Kouadir M. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors [J]. Cell Death Dis,?2019,10(2):128.
[17] Py BF, Kim MS, Vakifahmetoglu-Norberg H,et al. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity[J]. Mol Cell,2013,49(2):331-338.
[18] Juliana C, Fernandes-Alnemri T, Kang S,et al. Nontranscriptional priming and deubiquitination regulate NLRP3 inflammasome activation [J]. J Biol Chem,2012,287(43):36617-36622.
[19] Guo H, Callaway JB, Ting JPY. Inflammasomes :mechanism of action role in disease,and therapeutics[J]. Nat Med,2015,21(7):677-687.
[20] Cai X, Chen J, Xu H,et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation[J]. Cell,2014,156(6):1207-1222.
[21] Murakami T, Ockinger J, Byles J,et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome [J]. Proc Natl Acad Sci U S A,2011,109(28):11282-11287.
[22] Shi H, Wang Y, Li X,et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7 ,a new inflammasome component[J]. Nat Immunol,2016,17(3):250-258.
[23] He Y, Zeng MY, Yang D,et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux [J]. Nature,2016,530(7590):354-357.
[24] Shenoy AR, Wellington DA, Kumar P,et al. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals [J]. Science,2012,336(6080):481-485.
[25] Schmid-Burgk JL, Chauhan D, Schmidt T,et al. A genome-wide CRISPR (clustered regularly interspaced short palindromic repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation[J]. J Biol Chem,2016,291(1):103-109.
[26] Yao C,Veleva T,Scott L,et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation[J]. Circulation,2018,138(20):2227-2242.
[27] 夏平,杨浩. 炎症与心房颤动相关性的研究进展[J]. 心血管病学进展,2015,36(5):637-641.
[28] Qu YC ,Du YM,Wu SL,et al. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation [J] . Scand Cardiovasc J,2009,43(5):292-297.
[29] Okumura Y ,Watanabe I,Nakai T,et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation:Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence[J]. J Cardiovasc Electrophysiol,2011,22(9):987-993.
[30] Saba S, Janczewski AM, Baker LC,et al. Atrial contractile dysfunction,fibrosis,and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-alpha[J]. Am J Physiol Heart Circ Physiol,2005,289(4),H1456-H1467.
[31] Lee SH, Chen YC, Chen YJ,et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes[J]. Life Sci,2007,80(19),1806-1815.
[32] Qiu H,Ji C,Liu W,et al. Chronic kidney disease increases atrial fibrillation inducibility:involvement of inflammation,atrial fibrosis,and connexins[J]. Front Physiol,?2018,9:1726.
[33] Gungor B ,Ekmekci A,Arman A,et al. Assessment of interleukin-1 gene cluster polymorphisms in lone atrial fibrillation :new insight into the role of inflammation in atrial fibrillation[J]. Pacing Clin Electrophysiol,2013,36(10):1220-1227.
[34] He G,Tan W,Wang B,et al. Increased M1 macrophages infiltration is associated with thrombogenesis in rheumatic mitral stenosis patients with atrial fibrillation[J]. PLoS One,?2016,11(3):e0149910.
[35] Luan Y,Guo Y,Li S,et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease [J]. Europace,?2010,12(12):1713-1718.
[36] Sun Z,Zhou D,Xie X,et al. Cross-talk between macrophages and atrial myocytes in atrial fibrillation [J]. Basic Res Cardiol,?2016,111(6):63.
[37] Matsushita N,Ishida N,Ibi M,et al. IL-1β plays an important role in pressure overload-induced atrial fibrillation in mice[J]. Biol Pharm Bull,2019,42(4):543-546.
[38] Qiu H,Liu W,Lan T,et al. Salvianolate reduces atrial fibrillation through suppressing atrial interstitial fibrosis by inhibiting TGF-β1/Smad2/3 and TXNIP/NLRP3 inflammasome signaling pathways in post-MI rats [J]. Phytomedicine,2018,51:255-265.
[39] Monnerat G,Alarcón ML,Vasconcellos LR,et al. Macrophage-dependent IL-1 production induces cardiac arrhythmias in diabetic mice[J]. Nat Commun,?2016,7:13344.
[40] Ridker PM ,Everett BM,Thuren T,et al. Anti -inflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(6):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(6):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(6):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(6):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(6):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]